Sage Therapeutics, Inc. (Nasdaq: SAGE) ("Sage" or "the Company"), today announced that its Board of Directors has initiated a process to explore strategic alternatives for the Company. The Board ...

(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of ...

Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own ...

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Investing.com -- Sage Therapeutics, Inc. (NASDAQ: SAGE) stock climbed 2.5% today, reflecting investor sentiment after the company announced the initiation of a strategic review process and the ...

In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on SAGE Therapeutics (SAGE – Research Report), with a ...

Biogen Inc. shares climbed 1.7% on Monday afternoon, reaching a nearly two-week high, as positive regulatory news countered ...

Sage Therapeutics has rejected a buyout bid from partner Biogen and launched a review of strategic alternatives. Sage on Monday said its board determined that Biogen's $7.22-a-share proposal ...

In October last year, Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone) in postpartum depression. The company ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...